CASCINU, Stefano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 18.729
EU - Europa 6.003
AS - Asia 2.878
SA - Sud America 36
AF - Africa 33
Continente sconosciuto - Info sul continente non disponibili 21
OC - Oceania 20
Totale 27.720
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 18.651
GB - Regno Unito 2.109
IT - Italia 1.085
CN - Cina 881
SG - Singapore 769
SE - Svezia 628
DE - Germania 605
HK - Hong Kong 465
IE - Irlanda 428
UA - Ucraina 392
TR - Turchia 324
FI - Finlandia 219
BG - Bulgaria 187
FR - Francia 147
VN - Vietnam 111
IN - India 84
ID - Indonesia 78
CA - Canada 69
JP - Giappone 43
BE - Belgio 37
LT - Lituania 26
MY - Malesia 26
EG - Egitto 24
IQ - Iraq 24
RU - Federazione Russa 24
TW - Taiwan 22
BR - Brasile 19
NL - Olanda 19
EU - Europa 17
IR - Iran 17
ES - Italia 16
AU - Australia 15
RO - Romania 15
CH - Svizzera 12
CZ - Repubblica Ceca 11
KR - Corea 11
NO - Norvegia 8
CL - Cile 7
MX - Messico 6
GH - Ghana 5
MT - Malta 5
NZ - Nuova Zelanda 5
PK - Pakistan 5
PT - Portogallo 5
A2 - ???statistics.table.value.countryCode.A2??? 4
AT - Austria 4
BD - Bangladesh 4
LU - Lussemburgo 4
PH - Filippine 4
AR - Argentina 3
BZ - Belize 3
EC - Ecuador 3
IS - Islanda 3
PL - Polonia 3
IL - Israele 2
KH - Cambogia 2
KZ - Kazakistan 2
MD - Moldavia 2
MK - Macedonia 2
PE - Perù 2
SI - Slovenia 2
VE - Venezuela 2
AE - Emirati Arabi Uniti 1
BN - Brunei Darussalam 1
DK - Danimarca 1
ET - Etiopia 1
GR - Grecia 1
HR - Croazia 1
KE - Kenya 1
LV - Lettonia 1
MA - Marocco 1
MO - Macao, regione amministrativa speciale della Cina 1
OM - Oman 1
SK - Slovacchia (Repubblica Slovacca) 1
ZM - Zambia 1
Totale 27.720
Salva come PNG Salva come JPEG
Città #
Fairfield 3.260
Woodbridge 1.816
Southend 1.682
Ashburn 1.498
Houston 1.437
Seattle 1.277
Chandler 1.195
Cambridge 1.028
Wilmington 1.002
Santa Clara 813
Jacksonville 744
Ann Arbor 736
Dearborn 736
Singapore 581
Nyköping 473
Hong Kong 462
Dublin 424
Modena 306
Beijing 276
San Diego 243
Izmir 219
Princeton 188
Sofia 187
Eugene 174
New York 126
Helsinki 108
Dong Ket 103
London 92
Falls Church 85
Jakarta 75
Bremen 63
Fremont 60
Milan 60
Boardman 58
Shanghai 58
Redwood City 56
Ottawa 47
San Giuliano Milanese 36
Brussels 33
Phoenix 33
Guangzhou 29
Munich 29
Norwalk 29
Rome 27
Hefei 26
Bologna 23
Asyut 21
Baghdad 21
Kilburn 20
Tokyo 20
Nanjing 19
Chiswick 18
Frankfurt am Main 17
Kunming 16
Jinan 15
Banqiao 14
Florence 14
Paris 14
Siena 14
Absecon 13
Napoli 13
Des Moines 12
Hounslow 12
Los Angeles 12
Dallas 11
San Mateo 11
Toronto 11
Hangzhou 10
Brno 9
Chengdu 9
Chicago 9
Detroit 9
Fuzhou 9
Indiana 9
Parma 9
Augusta 8
Grafing 8
Mountain View 8
Mumbai 8
Shenyang 8
Wuhan 8
Hanoi 7
Hyderabad 7
Prescot 7
Sassuolo 7
Verona 7
Xian 7
Brooklyn 6
Carpi 6
Edinburgh 6
Genoa 6
Gunzenhausen 6
Istanbul 6
Nanchang 6
Piacenza 6
San Jose 6
San Marco 6
Tappahannock 6
Zhengzhou 6
Acri 5
Totale 22.571
Salva come PNG Salva come JPEG
Nome #
Cancer Treatment Induced Bone Loss (CTIBL) in breast cancer women: a multidisciplinary approach at the Modena Cancer Center screening over 600 patients. 395
GD2 expression in breast cancer. 298
Impact of time to surgery after neoadjuvant chemotherapy in operable breast cancer patients 275
Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer 268
Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going 260
Endocrine sensitive metastatic breast cancer and bone only disease: are the new treatments always better? 256
BRAF ,NRASandC-KITAdvanced Melanoma: Clinico-pathological Features, Targeted-Therapy Strategies and Survival 248
Transient sunitinib resistance in gastrointestinal stromal tumors. 228
Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus 228
Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status. 223
A Dose-finding and Biomarker Evaluation Phase Ib Study of Everolimus in Association With 5-Fluorouracil and Pelvic Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Cancer (E-LARC Study) 219
M09Quantification of circulating cell-free DNA by fluorimetry (Qubit) and spectrophotometry (NanoDrop) in patients with malignant melanoma and prostate cancer 213
Atrial fibrillation in patients with active malignancy and use of anticoagulants: Under-prescription but no adverse impact on all-cause mortality 211
Post-surgical pyoderma gangrenosum of the breast: needs for early diagnosis and right therapy. 208
Metronomic Capecitabine Effectively Blocks Leptomeningeal Carcinomatosis From Breast Cancer: A Case Report and Literature Review. 207
Hereditary pancreatic cancer: A retrospective single-center study of 5143 Italian families with history of BRCA-related malignancies 206
Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients 205
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? 204
Angiogenesis in pancreatic ductal adenocarcinoma: A controversial issue 202
Quality of life and anxious-depressive symptoms in cancer patients undergoing mindfulness-based interventions: Feasibility and preliminary outcomes on prospective single-centre case-control study (MIND4ME St.) 199
Randomized trial of low-dose morphine versus weak opioids in moderate cancer pain 199
Impact of body composition parameters on tumor response to neoadjuvant chemotherapy in operable breast cancer patients. 198
ERBB2 mutations in hormone receptor positive primary breast cancers samples and in their matched endocrine-resistant recurrences. 197
Osteonecrosis of the Jaw in a Breast Cancer Patient Treated with Everolimus and a Single Dose of Zoledronic Acid. 197
Predictive role of haemoglobin on disease response to neoadjuvant chemotherapy in breast cancer. 196
Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients. 196
Clinical and molecular analysis of long-term HER2 positive metastatic breast cancer survivors. 195
First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: Final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial 195
Tumor VEGF expression correlates with tumor stage and identifies prognostically different groups in patients with clear cell renal cell carcinoma 193
5-Fluorouracil pharmacogenomics: still rocking after all these years? 190
Combined Hormonal Contraceptive Use and Risk of Breast Cancer in a Population of Women With a Family History 190
Il trattamento di prima e seconda linea nel carcinoma gastrico 189
Gastrointestinal neuroendocrine tumors: Searching the optimal treatment strategy-A literature review 187
Are post-docetaxel treatments effective in patients with castration-resistant prostate cancer and performance of 2? A meta-analysis of published trials. 185
The evolving role of microsatellite instability in colorectal cancer: A review 182
Androgen receptor expression in early triple-negative breast cancer: clinical significance and prognostic associations. 182
The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer 181
Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials 179
VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study 178
Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat? 178
[11C]-Methionine Positron Emission Tomography in the Postoperative Imaging and Followup of Patients with Primary and Recurrent Gliomas 176
A novel approach to manage skin toxicity caused by therapeutic agents targeting epidermal growth factor receptor. 175
Role of evaluating tumor‑infiltrating lymphocytes, programmed death‑1 ligand 1 and mismatch repair proteins expression in malignant mesothelioma 175
Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New 173
Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status 172
Safety and efficacy of T-DM1 in HER2 positive metastatic breast cancer patients: a real word experience. 172
Primary and secondary prevention to effectively reduce the risk of bisphosphonate-related osteonecrosis of the jaw in patients with bone metastases . 172
Multimodal treatment of resectable pancreatic ductal adenocarcinoma 172
Adjuvant chemotherapy in colon cancer: can we improve quality of care? 170
Reply to O. Corli et al and M. Lucchesi et al 170
Cancer stem cell gene profile as predictor of relapse in high risk stage II and stage III, radically resected colon cancer patients. 169
Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier) 169
Prognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapy 168
Quantification of circulating cell-free DNA by fluorimetry (Qubit) and spectrophotometry (NanoDrop) in patients with malignant melanoma and prostate cancer 168
A randomized, double blind, placebo-controlled study to assess QTc interval prolongation of standard dose aflibercept in cancer patients treated with docetaxel. 168
Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale 168
ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib 167
Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma. 166
The Italian Rare Pancreatic Exocrine Cancer Initiative 163
Allele polymorphisms of tumor integrins correlate with peritoneal carcinosis capability of gastric cancer cells in radically resected patients. 163
Clinical evidence for three distinct gastric cancer subtypes: time for a new approach. 162
Molecular profile in primary and metastatic breast cancer treated with Exemestane and Everolimus. 162
Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab. 162
Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol 162
Thymic neoplasms: an update on the use of chemotherapy and new targeted therapies. A literature review. 161
A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer. 161
Tumor Angiogenesis: A Target for Renal Cell Carcinoma Therapy.Current Perspectives and Novel Strategies 161
Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR-TKIs and mTOR inhibitor. 160
Protracted low doses of temozolomide for the treatment of patients with recurrent glioblastoma: A phase II study. 160
Progress of molecular targeted therapies for advanced renal cell carcinoma. 160
Selecting the best treatment for an individual patient. 160
The role of LDH serum levels in predicting global outcome in HCC patients undergoing TACE: implications for clinical management. 160
The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management 160
The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab. 159
Role of vascular endothelial growth factor (VEGF) and VEGF-R genotyping in guiding the metastatic process in pT4a resected gastric cancer patients. 159
Phase II study of pharmacogenetic-tailored therapy in elderly colorectal cancer patients. 158
Correlation of Stomatitis and Cutaneous Toxicity With Clinical Outcome in Patients With Metastatic Renal-Cell Carcinoma Treated With Everolimus 158
Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients. 158
Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma 158
Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib 158
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. 157
eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: Final results of the ePHAS study 157
Sub-cellular localization analysis of MSH6 missense mutations does not reveal an overt MSH6 nuclear transport impairment. 156
Gastro-entero-pancreatic neuroendocrine tumors: Is now time for a new approach? 156
The prognostic role of hemoglobin levels in patients undergoing concurrent chemo-radiation for anal cancer 156
FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study. 155
State of the art for cardiotoxicity due to chemotherapy and to targeted therapies: a literature review. 155
Predictive Role Of Body Composition Parameters In Operable Breast Cancer Patients Treated With Neoadjuvant Chemotherapy. 155
First-Line Treatment for Endocrine-Sensitive Bone-Only Metastatic Breast Cancer: Systematic Review and Meta-analysis 155
Neutrophil-to-lymphocyte ratio may be associated with the outcome in patients with prostate cancer 153
Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma 153
Nuclear factor-κB predicts outcome in locally advanced rectal cancer patients receiving neoadjuvant radio-chemotherapy. 152
Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation. 152
Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: A retrospective study 152
Novel small molecule EGFR inhibitors as candidate drugs in non-small cell lung cancer. 151
Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study. 151
Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin 151
Class 1, 2, and 3 BRAF-mutated metastatic colorectal cancer: A detailed clinical, pathologic, and molecular characterization 151
Tumor angiogenesis genotyping and efficacy of first-line chemotherapy in metastatic gastric cancer patients. 150
Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: a randomized phase II trial. 150
Totale 18.203
Salva come PNG Salva come JPEG
Categoria #
all - tutte 111.975
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 111.975
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204.982 0 0 0 0 655 1.119 1.063 707 695 271 345 127
2020/20215.407 543 202 445 436 604 469 420 647 307 567 376 391
2021/20223.569 237 431 328 152 98 248 184 192 381 351 654 313
2022/20233.576 418 361 223 319 411 422 54 283 771 44 150 120
2023/20242.059 77 117 116 194 425 121 256 350 43 54 95 211
2024/20251.927 276 93 122 463 973 0 0 0 0 0 0 0
Totale 28.066